text:
For US Healthcare Professionals
For Patients and Caregivers
ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
ACTEMRA is indicated for the treatment of giant cell arteritis (GCA) in adult patients.
ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older.
ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.
RISK OF SERIOUS INFECTIONS:
Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled.
Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before ACTEMRA use and during therapy. Treatment for latent infection should be initiated prior to ACTEMRA use.
Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
Bacterial, viral and other infections due to opportunistic pathogens.
The risks and benefits of treatment with ACTEMRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ACTEMRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.
CONTRAINDICATION
ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA.
WARNINGS AND PRECAUTIONS
Gastrointestinal Perforations
Events of gastrointestinal (GI) perforation have been reported in clinical trials, primarily as complications of diverticulitis in RA patients. Use ACTEMRA with caution in patients who may be at increased risk for GI perforation. Promptly evaluate patients presenting with new-onset abdominal symptoms for early identification of GI perforation.
Hepatotoxicity
Serious cases of hepatic injury have been observed in patients taking intravenous or subcutaneous ACTEMRA. Some of these cases have resulted in liver transplant or death. Time to onset for cases ranged from months to years after treatment initiation. Most cases presented with marked elevations of transaminases (> 5 times ULN), and some cases presented with signs or symptoms of liver dysfunction and only mildly elevated transaminases.
Treatment with ACTEMRA was associated with a higher incidence of transaminase elevations; increased frequency and magnitude of these elevations were observed when ACTEMRA was used in combination with potentially hepatotoxic drugs (e.g., methotrexate).
It is not recommended to initiate ACTEMRA treatment in patients with elevated transaminases ALT or AST greater than 1.5x ULN. In patients who develop elevated ALT or AST greater than 5x ULN discontinue ACTEMRA.
Measure liver tests promptly in patients who report symptoms that may indicate liver injury. If the patient is found to have abnormal liver tests, ACTEMRA treatment should be interrupted. ACTEMRA should only be restarted in patients with another explanation for the liver test abnormalities after normalization of the liver tests.
Laboratory Parameters
Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Dosage modifications may be required.
Neutropenia: Treatment with ACTEMRA was associated with a higher incidence of neutropenia. It is not recommended to initiate ACTEMRA treatment in patients with a low neutrophil count i.e., absolute neutrophil count (ANC) less than 2000 per mm3. In patients who develop an ANC less than 500 per mm3 treatment is not recommended.
Thrombocytopenia: Treatment with ACTEMRA was associated with a reduction in platelet counts. It is not recommended to initiate ACTEMRA in patients with a platelet count below 100,000 per mm3. In patients who develop a platelet count less than 50,000 per mm3, treatment is not recommended.
Elevated Liver Enzymes: It is not recommended to initiate ACTEMRA treatment in patients with elevated transaminases ALT or AST >1.5x ULN. In patients who develop elevated ALT or AST >5x ULN, treatment is not recommended.
Lipid Abnormalities: Treatment with ACTEMRA was associated with increases in lipid parameters such as total cholesterol, triglycerides, LDL cholesterols, and/or HDL cholesterol.
The impact of treatment with ACTEMRA on the development of malignancies is not known, but malignancies were observed in clinical studies with ACTEMRA. ACTEMRA is an immunosuppressant, and treatment with immunosuppressants may result in an increased risk of malignancies.
Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, have been reported in association with ACTEMRA and anaphylactic events with a fatal outcome have been reported with intravenous infusion of ACTEMRA. ACTEMRA for intravenous use should only be infused by a healthcare professional with appropriate medical support to manage anaphylaxis. For ACTEMRA subcutaneous injection, advise patients to seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Do not administer ACTEMRA to patients with known hypersensitivity to ACTEMRA.
Anaphylaxis and other hypersensitivity reactions that required treatment discontinuation were reported in 0.1% (3 out of 2644) of patients in the 6-month controlled trials of intravenous ACTEMRA, 0.2% (8 out of 4009) of patients in the intravenous all-exposure RA population, 0.7% (8 out of 1068) in the subcutaneous 6-month controlled RA trials, and in 0.7% (10 out of 1465) of patients in the subcutaneous all-exposure population. In the SJIA controlled trial with intravenous ACTEMRA, 1 out of 112 patients (0.9%) experienced hypersensitivity reactions that required treatment discontinuation. In the PJIA controlled trial with intravenous ACTEMRA, 0 out of 188 patients (0%) in the ACTEMRA all-exposure population experienced hypersensitivity reactions that required treatment discontinuation.
Demyelinating Disorders
The impact of treatment with ACTEMRA on demyelinating disorders is not known, but multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were reported rarely in clinical studies. Monitor patients for signs and symptoms of demyelinating disorders. Prescribers should exercise caution in considering the use of ACTEMRA in patients with preexisting or recent-onset demyelinating disorders.
Active Hepatic Disease and Hepatic Impairment
Treatment with ACTEMRA is not recommended in patients with active hepatic disease or hepatic impairment.
Avoid use of live vaccines concurrently with ACTEMRA. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving ACTEMRA or on the effectiveness of vaccination in patients receiving ACTEMRA. Patients should be brought up to date on all recommended vaccinations prior to initiation of ACTEMRA therapy.
The most common serious adverse reactions were serious infections. The most common serious infections included pneumonia, urinary tract infection, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis. In the ACTEMRA-IV monotherapy clinical study, the rate of serious infections was 3.6 per 100 patient-years in the ACTEMRA group and 1.5 per 100 patient-years in the methotrexate group. The rate of serious infections in the 4 mg/kg and 8 mg/kg ACTEMRA plus DMARD groups was 4.4 and 5.3 events per 100 patient-years, respectively, compared to 3.9 events per 100 patient-years in the placebo plus DMARD group.
In the 5 Phase III clinical trials, the most common adverse reactions (≥5% of patients treated with ACTEMRA-IV) through 6 months were:
ACTEMRA-IV
Monotherapy (%)
Methotrexate (%)
+ DMARDs (%)
URTI 7 5 6 8 6
Nasopharyngitis 7 6 4 6 4
Headache 7 2 6 5 3
Hypertension 6 2 4 4 3
Increased ALT 6 4 3 3 1
The safety observed for ACTEMRA administered subcutaneously was consistent with the known safety profile of intravenous ACTEMRA, with the exception of injection-site reactions, which were more common with ACTEMRA-SC compared with placebo-SC injections (IV-arm).
In the 6-month control period, in SC-I, the frequency of injection-site reactions was 10.1% (64/631) and 2.4% (15/631) for the weekly ACTEMRA-SC and placebo-SC (IV-arm) group, respectively. In SC-II, the frequency of injection-site reactions was 7.1% (31/437) and 4.1% (9/218) for the every other week ACTEMRA-SC and placebo-SC groups, respectively. These injection-site reactions were mild to moderate in severity. The majority resolved without any treatment and none necessitated drug discontinuation.
GIANT CELL ARTERITIS (GCA)
The overall safety profile observed in the ACTEMRA treatment groups was generally consistent with the known safety profile of ACTEMRA. There was an overall higher incidence of infections in GCA patients relative to RA patients.
The rate of infections was 200.2 per 100 patient-years in the ACTEMRA SC weekly group and 160.2 per 100 patient-years in the ACTEMRA SC every other week group, as compared to 156.0 per 100 patient-years in the placebo + 26 week prednisone taper and 210.2 per 100 patient-years in the placebo + 52 week taper groups.
The rate of serious infections was 9.7 per 100 patient-years in the ACTEMRA SC weekly group and 4.4 per 100 patient-years in the ACTEMRA SC every other week group, as compared to 4.2 per 100 patient-years in the placebo + 26 week prednisone taper and 12.5 per 100 patient-years in the placebo + 52 week prednisone taper groups.
POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA)
The most common adverse events seen in ACTEMRA-IV all-exposure population included: upper respiratory tract infections, headache, nasopharyngitis, and diarrhea.
The rate of infections in the ACTEMRA-IV all-exposure population was 163.7 per 100 patient-years. The most common events observed were nasopharyngitis and upper respiratory tract infections. The rate of serious infections was numerically higher in patients weighing less than 30 kg treated with 10 mg/kg ACTEMRA-IV (12.2 per 100 patient-years) compared to patients weighing at or above 30 kg, treated with 8 mg/kg ACTEMRA-IV (4.0 per 100 patient-years). The incidence of infections leading to dose interruptions was also numerically higher in patients weighing less than 30 kg treated with 10 mg/kg ACTEMRA-IV (21%) compared to patients weighing at or above 30 kg, treated with 8 mg/kg ACTEMRA-IV (8%).
Infusion Reactions
In PJIA patients, infusion-related reactions are defined as all events occurring during or within 24 hours of an infusion. In the ACTEMRA-IV all-exposure population, 11 patients (6%) experienced an event during the infusion, and 38 patients (20.2%) experienced an event within 24 hours of an infusion. The most common events occurring during infusion were headache, nausea and hypotension, and occurring within 24 hours of infusion were dizziness and hypotension.
In general, the safety observed for ACTEMRA administered subcutaneously was consistent with the known safety profile of intravenous ACTEMRA, with the exception of injection site reactions (ISRs), and neutropenia.
During the 1-year study, a frequency of 28.8% (15/52) ISRs was observed in ACTEMRA-SC treated PJIA patients. These ISRs occurred in a greater proportion of patients at or above 30 kg (44.0%) compared with patients below 30 kg (14.8%). All ISRs were mild in severity and none of the ISRs required patient withdrawal from treatment or dose interruption.
During routine laboratory monitoring in the ACTEMRA-SC all exposure population, a decrease in neutrophil counts below 1 × 109 per L occurred in 15.4% of patients, and was more frequently observed in the patients less than 30 kg (25.9%) compared to patients at or above 30 kg (4.0%). There was no clear relationship between decreases in neutrophils below 1 x 109 per L and the occurrence of serious infections.
SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA)
The most common adverse events (at least 5%) seen in ACTEMRA-IV treated patients in the 12-week controlled portion of the study were: upper respiratory tract infections, headache, nasopharyngitis, and diarrhea.
In the 12-week controlled phase, the rate of all infections in the ACTEMRA-IV group was 345 per 100 patient-years and 287 per 100 patient-years in the placebo group. In the open-label extension over an average duration of 73 weeks of treatment, the overall rate of infections was 304 per 100 patient-years.
In the 12-week controlled phase, the rate of serious infections in the ACTEMRA-IV group was 11.5 per 100 patient-years. In the open-label extension over an average duration of 73 weeks of treatment, the overall rate of serious infections was 11.4 per 100 patient-years. The most commonly reported serious infections included pneumonia, gastroenteritis, varicella, and otitis media.
Macrophage Activation Syndrome
In the 12-week controlled study, no patient in any treatment group experienced macrophage activation syndrome (MAS) while on assigned treatment; 3 per 112 (3%) developed MAS during open-label treatment with ACTEMRA-IV. One patient in the placebo group escaped to ACTEMRA-IV 12 mg per kg at Week 2 due to severe disease activity, and ultimately developed MAS at Day 70. Two additional patients developed MAS during the long-term extension. All 3 patients had ACTEMRA-IV dose interrupted (2 patients) or discontinued (1 patient) for the MAS event, received treatment, and the MAS resolved without sequelae. Based on a limited number of cases, the incidence of MAS does not appear to be elevated in the ACTEMRA-IV SJIA clinical development experience; however, no definitive conclusions can be made.
In the 12-week controlled phase, 4% of ACTEMRA-IV and 0% of placebo-treated patients experienced events occurring during infusion.
Within 24 hours after infusion, 16% of patients in the ACTEMRA-IV treatment group and 5% of patients in the placebo group experienced an event. In the ACTEMRA-IV group the events included rash, urticaria, diarrhea, epigastric discomfort, arthralgia, and headache. One of these events, urticaria, was considered serious.
Anaphylaxis was reported in 1 out of 112 patients (less than 1%) treated with ACTEMRA-IV during the controlled and open-label extension study.
In general, the safety observed for ACTEMRA administered subcutaneously was consistent with the known safety profile of intravenous ACTEMRA, with the exception of Injection Site Reactions (ISRs).
A total of 41.2% (21/51) SJIA patients experienced ISRs to ACTEMRA-SC. The most common ISRs were erythema, pruritus, pain, and swelling at the injection site. The majority of ISRs reported were Grade 1 events and all ISRs reported were non-serious and none required patient withdrawal from treatment or dose interruption.
In GCA patients, no effect of concomitant corticosteroid on ACTEMRA exposure was observed.
Cytochrome P450s in the liver are down-regulated by infection and inflammation stimuli including cytokines such as IL-6. Inhibition of IL-6 signaling in RA patients treated with ACTEMRA may restore CYP450 activities to higher levels than those in the absence of ACTEMRA leading to increased metabolism of drugs that are CYP450 substrates.
Exercise caution when coadministering ACTEMRA with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc.
USE IN PREGNANCY
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ACTEMRA during pregnancy. Physicians are encouraged to register patients and pregnant women are encouraged to register themselves by calling 1-877-311-8972.
The limited available data with ACTEMRA in pregnant women are not sufficient to determine whether there is a drug-associated risk for major birth defects and miscarriage.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see additional Important Safety Information in full Prescribing Information, including BOXED WARNING.
About ACTEMRA
Prescribing Information
PJIA
SJIA
Pivotal Trials
Monotherapy
Dosing & Monitoring
Dosing Schedule
ACTEMRA Clinical Safety Study
Pregnancy Registry Safety
Patient Financial Support
Patient Education & Training
GENENTECH HAS CUSTOMIZED SUPPORT TO HELP PATIENTS ACCESS ACTEMRA
With the ACTEMRA Co-pay Card Program, eligible, commercially insured patients pay as little as $5/drug co-pay.* The card is valid for up to $15,000 of co-pay assistance within a 12-month period.
Answer a few questions below to see if your patient qualifies.
Find the right assistance option for your patients.
Is your patient insured?
Does the patient's insurance cover his or her Genentech medicine?
Does your patient have commercial insurance?
Has your patient already been referred to the ACTEMRA Co-pay Card Program and is either ineligible or no longer receiving assistance?
Has your patient already been referred to an independent co-pay assistance foundation and is either ineligible or no longer receiving assistance?
Is the patient using ACTEMRA for an FDA-approved indication?
Your Patient Might Qualify for a Referral to the ACTEMRA Co-pay Card Program
If eligible commercially insured patients need assistance with their out-of-pocket costs, Genentech Rheumatology Access Solutions can refer them to the ACTEMRA Co-pay Card Program.*
*In order to be eligible for the ACTEMRA Co-pay Card Program, the patient must have commercial insurance, must not have Medicare, Medicaid or other government insurance, and must meet other eligibility criteria. They also must agree to the rules set forth in the terms and conditions for the program. Please visit RACopay.com for the full list of terms and conditions.
Your Patient Might Qualify for a Referral to an Independent Co-pay Assistance Foundation
For eligible patients with commercial or public health insurance, Genentech Rheumatology Access Solutions offers referrals to independent co-pay assistance foundations.*
Note: Patients who were prescribed ACTEMRA Subcutaneous (SC) and have a Medicare Advantage or Medicare Part D plan may qualify for financial assistance with their Medicare prescription drug costs through the Low-Income Subsidy (LIS), also known as Extra Help. Learn more or apply for Extra Help from Medicare at https://secure.ssa.gov/i1020/start.
*Genentech does not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Genentech Rheumatology Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech's endorsement or financial support. There may be other foundations to support the patient's disease state.
Your Patient Might Qualify for a Referral to the Genentech Patient Foundation
The Genentech Patient Foundation provides free Genentech medicine to people who don't have insurance coverage or who have financial concerns and to people who meet certain income criteria.*
*To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the ACTEMRA Co-pay Card Program and support from independent co-pay assistance foundations) and must meet financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.
Update Response
*The final amount owed by patients may be as little as $5, but may vary based on health insurance plan policies regarding manufacturer co-pay assistance programs.
Additional Patient Financial Support Information
Read Co-Pay FAQs
Patient awaiting a coverage decision
"My insurance company hasn't decided whether they will pay for my ACTEMRA SC. What can I do?"
ACT Fast Program
Eligible patients may receive ACTEMRA SC at no charge for up to 6 months or until the health plan makes a coverage decision—whichever comes first.
Any eligible patient
"I want to start my ACTEMRA SC treatment today. Do I need to wait until my prescription is shipped?"
ACTEMRA SC Sampling Program†
Provides samples to enable patients to receive same-day treatment and help patients learn to self-inject ACTEMRA. Samples may be requested from your clinical specialist here.
For more information, call: 1-800-ACTEMRA (1-800-228-3672), or click here
Co-pay Card Program Eligibility Requirements
This ACTEMRA Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid, or any other federal or state government program to pay for their medications are not eligible.
Under the program, the patient will pay a co-pay. After reaching the maximum program benefit, the patient will be responsible for all out-of-pocket costs.
All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this program. This program is void where prohibited by law. Genentech reserves the right to rescind, revoke, or amend the program without notice at any time. Additional eligibility criteria apply. See full terms and conditions at https://racopay.com/actemra/terms-and-conditions.
†Samples may not be sold, purchased or traded or offered for sale purchase or trade, utilized to seek reimbursement, or otherwise distributed in a manner not permitted by applicable law.
© [YEAR] Genentech USA, Inc. All rights reserved.
This site is intended for US residents only.
Link to Third Party Site
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
Link to Healthcare Professionals Site
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
Thanks for sharing this page.


text:
About Multiplex
Multiplex Advantage
Redefining Sustainability
John Flecker
« BACK TO MANAGEMENT LIST
John commenced with Multiplex Constructions as a Cadet Site Engineer in 1987 and progressed to CEO in 2011.
John is a founding Director of the Literacy for Life Foundation (a not for profit organisation focused on adult literacy in remote indigenous communities), a Director of the Green Building Council of Australia and a Board Member of the Australian Constructors Association. John also sits on the Board of Trustees of The Scotch College (WA) Foundation (Inc) and the school council. John is a fellow of the Institution of Engineers Australia.
Contact number: +61 8 9483 0899
Address: Level 1, 123 St George's Terrace, Perth WA 6000
Anti-Bribery Act
Anti-Modern Slavery Policy
Anti-Modern Slavery Charter
UK Modern Slavery 2018 Statement
Other Statements and Policies
© 2017. Multiplex is a Brookfield company.

redpajama_set_name: RedPajamaCommonCrawl


【Function】The triangle metric ruler can be used as a protractor, miter, line scriber, saw guide and tri/meter square, framing square and a ruler, ideal for all building and remodeling projects.
【High Quality】The carpenter square is manufactured of high quality aluminum alloy with black matte finish to prevent glare, corrosion resistant and durable, not easy to break.
【Two Measurements】Features metric and imperial measurements with clear graduation, embossed imperial graduations and common rafter conversion table, the triangle ruler squares is convenient for measuring and read.
THREE MEASURING MODES: One button quick change between two measuring modes: inch, millimeter. With one extra button battery.
PRECISION MEASUREMENT: Measurement Range: 0 – 6" and 0 – 150mm; Resolution: 0.01" / 0.1mm; Accuracy: 0.01" / 0.2mm.
EASY TO READING: Large LCD screen is easy and clear to reading. And the lightweight digital caliper can be carried and used at any time.
[3 Different Grippers for Various Needs] There're 2pcs auto-ratcheting wrenches with 3 grippers, and these universal grippers are suitable for nuts or bolts whose diameters are from 9mm to 32mm. And they can also be used for various shapes, like square, hexagonal, triangle and so on.
[Magic Self-adjust&Easy to Use] The grippers of N-grip spanners are adjustable, and you don't need spend too much time adjusting the size of gripper if you need remove nuts with different sizes&shapes, and you can operate it by one hand, so it can help save your time and energy.
[High Hardness&Durability] Made of high carbon steel, these pipe monkey spanners have high toughness&hardness and good grip. With the overall heat treatment&forging process, the torque of this crescent self -adjustable wrench spanner set is great. With self locking function, it's not easy to slip when you use these grippers.


For much of the 1950s and '60s, Sidney Poitier was the standard-bearer for all of black Hollywood, his stardom held aloft as a beacon of integration and progress. In reality, the movie industry remained largely segregated and out of step with the developments of the civil rights era; the Poitier mythology not only obscured this truth, but it also dwarfed the contributions of other African American actors, some of whom paved the way for Poitier's ascent.
No one deserves more credit for presaging the stereotype-breaking characters that Poitier perfected than James Edwards, who, in 1949, shot from anonymity to stardom in producer Stanley Kramer's controversial, race-infused war melodrama, "Home of the Brave." Gifted, outspoken and unwilling to accept the demeaning caricatures that blacks often played on-screen, Edwards was heralded as the first African American actor to topline a major studio feature in a straight dramatic role.
Since Edwards' early death in 1970, his iconic stature in African American cinema history has rarely been recognized. In "James Edwards: African American Hollywood Icon," author Pamala S. Deane admirably tries to remedy this oversight with a compelling-if-workmanlike account of a groundbreaking life and career that were at times starry, other times star-crossed.
Born in 1918 in Indiana, Edwards took up acting after serving in World War II, at a time when many playwrights tackled race relations and discrimination in their works. During his acclaimed stint playing a black ex-G.I. battling Jim Crow racism in one such play, "Deep Are the Roots," Edwards was hired to star in Kramer's low-budget war film, which was being developed in secrecy for fear its subject matter would ignite race riots.
In "Home of the Brave," Edwards portrayed Pvt. Peter Moss, the lone African American in a dangerous reconnaissance mission on a Japanese-held island. When a white soldier calls Moss the N word, Moss suffers an emotional breakdown and is cured by an empathetic white Army psychiatrist. The film's treatment of racism was considered bold; it was a hit, and Edwards toured the country as a celebrity and an ambassador between races. Edwards was "showered with awards, honored with his own parade, and given the keys to the city of Harlem," Deane writes.
But his stardom was short-lived, and in the 1950s and '60s, Edwards settled for a career as a sturdy, recognizable character actor. Except for a few prominent parts -- in Sam Fuller's 1951 Korean War drama "The Steel Helmet," the 1962 Cold War thriller "The Manchurian Candidate" and 1970's "Patton" -- Edwards had mostly undistinguished, second-tier film and television roles.
His situation was no different from that of other black actors trying to survive. In the two decades following Edwards' breakthrough in "Home of the Brave," the roles improved, but the percentage of African American employment in Hollywood didn't increase much, if at all.
Deane refuses to lay blame on institutional racism. The movie industry, she points out, was undergoing tremendous economic struggles in those years, and many once-prominent white actors were struggling as well. But the towering shadow of Poitier is discussed only briefly, and it becomes something of an elephant in the room. After his debut as a doctor in 1950's "No Way Out" -- Edwards was passed over for the role -- Poitier quickly supplanted Edwards as the black actor most associated with the liberal-minded "problem pictures" of the era.
Edwards' career may also have been hamstrung by his views. Emboldened by success, he spoke out against demeaning roles and criticized "Amos 'n' Andy" in particular. And when FBI agents pressured Edwards to testify before the House Un-American Activities Committee and disavow leftist actor Paul Robeson, Edwards refused. Deane hints that Edwards' political ties might have been a liability, but because his FBI file has been destroyed, she cannot verify this.
Edwards endured personal struggles, including failed financial ventures, extramarital affairs, charges of violence against women and rumors of heavy drinking. Though all these factors may have contributed to his fallen stardom, the real tragedy lay in the way the mainstream press largely forgot Edwards' contributions after he wore out his usefulness as a symbol.
The African American public and press didn't forget, however, and considered Edwards a star even if he never had another starring role. "To black citizens of the period, who often made a point of attending any film that included a black character, Edwards' presence," Deane writes, "was far from routine, but at times an event."
Ryfle is writing a book about Hollywood during the civil rights era.


Mill Valley roofing contractors need to know their craft. Being able to nail a shingle up on a roof doesnt make you a roofing contractor in Mill Valley or any other town in California. Believe it or not, there are so called roofers who are barely qualified, improperly licensed and in some cases, uninsured!
When a storm rips thru Mill Valley, CA you need a professional roofing contractor. When you need emergency services, roof repair or inspections, NorthBay Roofing & Gutters Inc. is the Mill Valley roofing contractor for the job.
Customers in the Mill Valley area, some of which may be your neighbors, have already discovered why NorthBay Roofing & Gutters Inc. is the number one choice among Mill Valley roofers.
Mill Valley, CA residents have discovered over the years why we are the best roofer in Mill Valley.
Mill Valley, CA area homes or businesses, call NorthBay Roofing & Gutters Inc. today at (707) 820-7663 to schedule a roof inspection and estimate.


We noted in June that Zimbabwe's cash crisis continued unabated.
Those awaiting cash transfers at a bank may wait a month to be cleared and, even then, the transfer may be refused.
And now it appears many Zimbabweans have found an alternate way to store/transfer wealth away from Mugabe's prying (and confiscatory) eyes.
In September we noted the hyperbitcoinization occurring in Zimbabwe. In October, Zimbabwe demand started to impact the global price of the cryptocurrency, and two weeks ago we noted the doubling of the price of Bitcoin in Zimbabwe as uncertainty about the nation's stability sent citizens into a decentralized currency that was out of Mugabe's reach.
Now, after the military coup confirms the average joe's fears, Bitcoin is trading at over $13,000 on Zimbabwe exchange Golix - a premium of over 80% over the USD exchange price as demand surged.
Bloomberg reports that demand for bitcoin in Zimbabwe has surged amid a shortage of hard currency.
Golix processed more than $1 million of transactions in the past 30 days, compared with turnover of $100,000 for the whole of 2016, according to data on the exchange's website.
Zimbabwe doesn't have its own currency, with the government adopting the U.S. dollar and South African rand, among others, as legal tender in 2009 after hyperinflation rendered the local dollar worthless.
According to a local trader, bitcoin isn't just being bought by individuals, but by businesses with bills to pay.
Bitcoin, as every bitcoiner would expect, is helping people in the country survive times of economic uncertainty, as Zimbabwe has been embroiled in a crisis for years.
As CoinTelegraph noted previously, Zimbabwe is beginning to act like an interesting case study for what happens when a country begins to collapse around its monetary system - it is also being witnessed in Venezuela.
Moving money out of Zimbabwe is starting to become impossible, and as people try and flee monetarily out of the crumbling state, they are finding refuge in Bitcoin.
Soon, banks in Zimbabwe have stated that Visa debit cards would no longer be usable for international payments without prior arrangements and pre-funding with hard currency.
"You will be required to make prior limit arrangements with the bank," Stanbic said in a message to depositors last week.
Econet Wireless has also stopped foreign payments on its MasterCard linked EcoCash mobile money debit card.
Because of the decentralized nature of Bitcoin, there is no impact on it from this political upheaval, in fact, it is only benefiting from it. The Bitcoin premium of almost 100 percent is not because of the political issues, rather the high demand surrounding worry of collapse.
Bitcoin again shows its potential and power when the banking system again shows its potential for mass collapse and hysteria.


In a skillet heat 1 tablespoon of the oil over moderate heat until it is hot and in it saute the chorizo for 1 minute. Add the onion and cook the mixture, stirring, until the onion is softened. Add the garlic and cook the mixture, stirring, for 1 minute. Add the mushroom stems and salt and pepper to taste and cook the mixture, stirring, until the liquid the mushrooms give off is evaporated. Add the Sherry and boil it until it is evaporated. Remove the skillet from the heat and stir in the breadcrumbs. Let the mixture cook and blend in the egg yolk, the parsley, and salt and pepper to taste.
Brush the outside of each mushroom cap with some of the oil. Divide the filling among the caps, mounding it, arrange the stuffed mushrooms in a lightly oiled baking dish just large enough to hold them in one layer, and bake them in a preheated 400 degree F. oven for 5 to 10 minutes, or until they are golden. Serve the mushrooms warm or at room temperature.


text:
About NBR
Next Generation Programs
Seattle Office
One Union Square, Suite 1012
600 University Street
Tel: +1.206.632.7370
1819 L St NW, Ninth Floor
Experts Home
Strategic Asia Program
People's Liberation Army Conference
PLA Executive Education
Energy Security Program
Maritime Awareness Project
Pacific Energy Summit
Commission on the Theft of American Intellectual Property
All Programs & Projects
Asia Policy
Strategic Asia
NBR Reports
Energy & Environmental Security
Cybersecurity & Technology
Health & Human Security
Topics Home
Admiral Jonathan W. Greenert
Admiral, U.S. Navy (ret.)
John M. Shalikashvili Chair
The National Bureau of Asian Research
Admiral Jonathan W. Greenert holds the John M. Shalikashvili Chair in National Security Studies at The National Bureau of Asian Research (NBR). At NBR, Admiral Greenert informs debates on critical issues in the Asia-Pacific through briefings to congressional members, military, media, and administration officials; meetings with senior-level counterparts in Asia; and research, speaking, and writing. Prior to joining NBR, he served as the 30th chief of naval operations from 2011 to 2015.
Admiral Greenert comes to NBR after a distinguished 40-year career in the U.S. Navy. A 1975 graduate of the U.S. Naval Academy (BS, Ocean Engineering), he completed studies in nuclear engineering for service as a submarine officer. His submarine career included numerous operational assignments, culminating in command of the USS Honolulu. His Asia-Pacific assignments included commander, Submarine Squadron 11; commander, U.S. Naval Forces Marianas; chief of staff and commander, U.S. 7th Fleet; and deputy commander, U.S. Pacific Fleet. He also served as commander, U.S. Fleet Forces Command, before becoming the 36th vice chief of naval operations from 2009 to 2011.
Admiral Greenert is a recipient of various personal and campaign awards, including the Distinguished Service Medal (six awards), Defense Superior Service Medal, and Legion of Merit (four awards). In 1992, he received the Vice Admiral Stockdale Award for inspirational leadership. He considers it his greatest reward to have served with and led the hundreds of thousands of sailors and civilians who volunteer to serve and protect the United States.
China's Shift to Gray-Zone Operations: Implications for the U.S.-Japan Alliance
Balancing the Costs of Covid-19: New Normal or Old Normal?
Navigating Contested Waters (Introduction)
U.S. Defense Strategy in the Indo-Pacific
Tenets of a Regional Defense Strategy: Considerations for the Indo-Pacific
Strengthening U.S.-Taiwan Defense Relations
Defining the Ends, Means, and Ways of SCS Strategy
Declaring Consistent Commitments: U.S. Maritime Policy in the Asia-Pacific
Murky Waters in the East China Sea: Chinese Gray-Zone Operations and U.S.-Japan Alliance Cooperation
Jonathan W. Greenert
Kenneth B. and Anne H.H. Pyle Center for Northeast Asia Studies
John M. Shalikashvili Chair in National Security Studies
Center for Innovation, Trade, and Strategy
Slade Gorton Policy Center
and follow us on Youtube Sign up for updates
Account Subscribe
©2023 The National Bureau of Asian Research
This site uses cookies. Please read our Privacy Policy to learn how and why we use cookies.


Custom orders and shoots are welcomed and encouraged! I can add on to any package or customize a package to meet your needs! Please contact me for further information regarding a photo shoot. I am very interested in doing more pet photography so if you want a special session with your pet (not just dog!) please contact me!


text:
Q: how to pass parameter to python script from a pipeline I am building an Azure Data Factory pipeline and I would like to know how to get this parameter into the python script.
The python script is located in Databricks (DBFS) and is run from Azure DataFactory. So, in my ADF pipeline, I have some parameters which I'd like to introduce and use them insinde the python script.
Any idea on how does it work?

A: Import argv from sys and then use argv[1] to get the parameter in databricks activity.

redpajama_set_name: RedPajamaStackExchange


text:
Wayne Grayson
Updated Oct 4, 2019
With Bobcat's Machine IQ wireless communication system generating heaps of useful data on machines in the field, the company has launched a new online dashboard for viewing it all.
Located at my.bobcat.com, the Bobcat Owner Portal website gives machine owners and fleet managers easy and quick access to machine location, operating hours, fuel level and machine maintenance alerts on the company's R-Series compact excavators and M2-Series skid-steer or compact track loaders.
Bobcat says the site, which can be personalized with custom machine names, can be viewed on any internet-connected device including smartphones, tablets and desktop or laptop computers.
The site provides customers with seven days of fault codes for connected machines, but also offers the option to subscribe to maintenance alert emails. These emails are sent whenever a machine generates a common fault code, or when machine maintenance is due, Bobcat says. The time-for-maintenance alerts also detail what parts they'll need for the needed maintenance and a service checklist for additional maintenance needs, the company says.
With this enhanced service monitoring, Bobcat says its dealers are better able to respond to customer needs for parts and service—often alerting customers to required maintenance before they're aware it's needed.
Beyond maintenance alerts, Bobcat Owner Portal can also send customers alerts when their machines leave a specified area, helping prevent theft. Bobcat says owners can also set curfews for their machines. These curfews trigger an alert whenever a machine is operated outside of designated hours.
For the future, Bobcat is planning on adding the ability to track machine efficiency and utilization in order to help owners make more informed decisions. The company is also planning to add a feature for fleet managers that allows them to get a better view of ownership costs.
Check out bobcat.com/owner-portal for more information, or see your local Bobcat dealer.
Bobcat's new R-Series skid-steers and CTLs are its toughest and most powerful yet


text:
Print and Play Demo
Conspire
Alexander Jerabek
Conspiring
Conspire is our next Cherry Picked game. While waiting for Drink! to cross the ocean, we started work on a hidden-role storytelling game. Drink! arrives at our doorstep tomorrow, so it feels like a good time to share Conspire's design and future.
Conspire is a hybrid of the hidden-role and storytelling genres. Hidden-role games revolve around the identity and intentions of the players remaining anonymous. Werewolf, Mafia, and The Resistance are some examples. Storytelling games are variants of role-playing games (the degree of distinction depends on your elitism). They typically have fewer rules and mechanics than their heavier cousins. Microscope and Fall of Magic would be examples of these (though games like Pathfinder and Catalyst also tell stories and are couched in narrative delivery and exploration). Basically, Conspire is a game where you are discussing a problem with people, but you do not know who everyone else is or what they want.
Here's the executive summary for Conspire's structure and rules. Players start by creating a scene; a moment in time and space rife with conflict and mystery. Every player adds a role to the scene they think belongs there. These roles are templates for players to flesh out in-character later. Then, a different player gives a role three goals to achieve during the forthcoming discussion. These goals are intended to oppose and compliment different roles, creating a tangled web of alliances and opposition. All the roles are shuffled once more and players enter the scene proper.
Through persuasion and negotiation, players try to achieve as many of their goals as possible before the scene ends. They have one other tool in the form of "influence". Each player gets three influence tokens to spend. Doing so makes something about the world become true. Such declarations can violate real-world physics, commonsense, or rational logic. The only restrictions are influence cannot remove agency from a player or contradict a previously established influence declaration or tenet of the scene. This all creates an absurd, hilarious, and positive storytelling environment.
Once the scene's conflict is resolved and players are evaluated on their goals, the group edits everything. They tweak goals and swap out roles. The scene is reset and play begins anew, with different people playing different roles with different objectives. This iteration makes the game unique to your group and highlights whatever elements you find entertaining.
The whole experience takes, at most, a couple hours. Conspire supports four to twelve players and leaves them laughing and reminiscing for days.
We are presenting Conspire as a book, the traditional storytelling-game format. This guide contains the rules of play, numerous examples, and even premade scenes to ease new groups into the genre. Jake Breish is illustrating the book, ensuring it is as pleasing visually as it is intellectually.
We are launching a Kickstarter in a few months to fund the initial print run. We are currently pricing everything and looking into additional rewards for our backers. We expect to launch the campaign in the fall and deliver in 2017.
Playtesting is an integral part of Cherry Picked culture. We have been running Conspire games since April and will continue to do so until launch. We need more testers of all experience levels, personality types, and backgrounds. Contact us for playtest kits.
To wrap things up, our creative director wants to share his thoughts going into the project.
I've had the premise of a hidden-role RPG in my head for a while. The catalyst for making Conspire our next game was Emerald City Comic Con. We ran games of Catalyst through Games on Demand with some other indie RPGs and storytelling games. We had done this before at PAX, but the GoD community at ECCC was much less inclusive. They had a very narrow idea of what constituted a "good" game and spent a lot of energy disparaging D&D, Pathfinder, and anything resembling a tradition RPG. This included Catalyst (and, paradoxically, Monsterhearts and other games they were running…) I took pride in having my Catalyst group laugh harder than anyone at their tables and I know my players had great experiences because of the game. However, I still thought a lot about their criticisms of GM-driven RPGs.
The basic argument is that rules restrict players and limit accessibility. I fundamentally disagree with that, instead believing structure helps players learn and inspires creativity. Indeed, I've seen far too many "player-centric" games dominated by big personalities or experienced story gamers due to the lack of a safety net for meeker players. Such games have manuals that seem enamored with giving players the ability to create; as if that is the stumbling point for players in other games. Creativity is inherent in people and not the part a game needs to explain.
In performing improv comedy, I've seen numerous audience volunteers come on stage and be creative. They go along with the scene and have no problem assuming an identity. They play the game. Their challenges are following the unwritten rules of improv: "yes-anding" others, finding the odd things in a scene for comedic effect, and leaning into the rules of a game to trigger audience reactions. Conspire is designed to help players with these parts of storytelling.
Conspire is "rules-light". Very few mechanics define play. The players are the ones to put boundaries on the scene and give explicit goals to each other. They make the rules to follow. In limiting the scene, it creates a clear world everyone understands and can exploit. The game tells you how to have fun, instead of letting you have a bad time and blaming it on your lack of creativity.
If you dislike storytelling games because of their ambiguously defined objectives or floaty, pretentious nature, you will love Conspire. If you do not like role-playing games because of numbers and math, you will love Conspire. If you do not like Werewolf because it becomes a rote logic puzzle, you will love Conspire. We want to take those awesome moments of deduction, wit, bluffing from Werewolf and put them in a scenario you and your friends care about. You are creating a personalized hidden-role game every round that taps into deep emotional and social instincts.
Come play Conspire. Help us refine it into the best storytelling game out there.
Tagged: design, inspiration, hating on haters
Newer PostDrink! Fulfillment
Older PostUpcoming Conventions
Cherry Picked Games, 5518 25th Avenue Northeast, Seattle, WA, 98105, United Statesalex@cherrypickedgames.com
Ⓒ Cherry Picked Games 2016-2018


Mary-Kate & Ashley star as twins Chloe and Riley Carlson in this hilarious new series, based on the hit TV show So Little Time.
" Set up a date between your two friends.
" Learn how to use power tools.
" Show the conceited boy whos boss.
" Hang out with your secret crush!
Chloe and Riley Carlson&So much to do&So Little Time!


Firm Finishing Hair Spray Compare to Paul Mitchell Extra-Body Firm Finishing Spray is rated 4.4 out of 5 by 18.
GVP Firm Finishing Spray delivers long-lasting, humidity resistant, firm hold.provides a firm, all day hold that will make your hair shiny and resistant to humidity. Contains a thickening agent that will provide volume and body. Compare to Paul Mitchell Extra-Body Finishing and save.
Spray on dry hair. Style as desired.
Rated 5 out of 5 by Consumer Advocate from Increases volume and texture Great hair spray for thin fine hair. It's the only spray I will use. It is amazing the difference it makes in increasing volume and texture!
Rated 5 out of 5 by CindaLee from Great product & holds your hair all day! This is the best hair spray.. and thats coming from a woman who was raised in the 80's - the big hair generation when our hair entered a room before we did! Your hair will not move after using this spray and a little bit goes a long way so you don't need to use much at all.
Rated 4 out of 5 by HumanUnicorn from As Good As PM Paul Mitchell recently downsized their cans from 12 to 8 ounces and for the same price, it pushed me over the edge. So, I went looking for a comparable product and this came up. Of course, I was skeptical because most of the time when they say "Compare to...." there's no comparison. BUT, this is pretty darn close. I'm taking one star off because the can lacks the wide-mouthed diffuser the PM brand has that helps it to spray wider and "drier". But, after a few days, I was used to how it sprayed. But, it holds just like the PM counterpart - which is why I liked the PM - it wasn't stiff but it also wasn't so wimpy that there wasn't any hold at all. And, you cannot beat the price difference. Three cans of PM was $60. Three cans of this (I got it on a buy 2 Get 1 Free) was less than $17. I'm a fan!
Rated 5 out of 5 by bosher70 from Good value I buy this regularly and love it. My hair is thin and fine. This product does not weigh down my hair, does not build up and it holds beautifully.
Rated 1 out of 5 by joany1963 from hair spray couldn't get canister to work. Nothing came out. I was very disappointed.
Rated 5 out of 5 by SparklyPinkTigger from Great Product This does exactly what it says it will. It holds well without using too much spray and it does not go on heavy. The finish is light and it does not look sprayed or plastered and stiff. I wish it had a nice fragrance though that is the only thing they could improve upon with this product. I have been using Chi firm hold hairspray for years and this works just as well for less $$. I've had this one now for almost a month and I would definitely buy this again.
Rated 5 out of 5 by Kelley from FINALLY!!! I have short(er) fine hair that is styled and I have to use a strong hold hairspray. Prior to trying this my favorite was CHI Helmet Head in the pump, the aerosol doesn't have the hold that the pump has however, having fine hair non-aerosols are a little wet and heavy. The hold was great but I was still looking for a better spray. This is it. Every other spray either didn't hold my hair well, took half a can to get any hold and/or worse dried my hair out so badly, it was horrible! The GVP PM Firm...holds better than anything with very little product and without stifness but I can hurricane proof my hair with this if need be with far less product than even the CHI Helmet Head, isn't sticky at all, doesn't break my hair off, I can spray a minute amount and get all day hold, rinses unbelievably fast from my hair, does not dry my hair out at all, looks shiny. Aside from the hold doesn't even look like I have hairspray on my hair. I couldn't be happier with this hairspray and the price is about 1/3 of the name brand yet works better. The only con is it doesn't smell great but the smell doesn't linger at all, I just smell my shampoo after this dries, and it dries fast. My nozzle was clogged when I bought it, a little alcohol cleaned it out no problem. Good stuff, will repurchase over and over and over again!
Can I purchase in the store with the same deal buy 2 get on free?
Can I use on synthetic hair?


text:
Adobe Releases Air 2.5 SDK
by Briley 13 November, 2010 12:49 pm0
Adobe recently released the Adobe Air 2.5 SDK development tools for download, which are meant to aid developers in creating applications for television, tablet PC, mobile smartphone and desktop operating systems.
The latest SDK release also includes additional support features for the existing Air code. One of the most prominent inclusions is the added support for accelerometers, allowing equipped mobile devices to be used in conjunction with apps and programs. The new release also added additional support for cameras, videos, integrated microphones, hand and finger screen gestures and multitouch compatibility.
Probably more interesting is the fact that the update also provides geo-location/GPS support, which means developers can now integrate location services into existing or future applications. In previous versions this was not readily accessible, and since its increasing and widespread use has garnered a higher demand. It is especially useful in unique social entertainment applications and programs.
Adobe Air provides support for a plethora of devices including but not limited to Android, iOS and RIM's QNX platforms.
According to David Wadhwani, Adobe's senior vice president of Creative and Interactive Solutions; the Adobe Air SDK will allow developers to create cross-platform applications without delegating separate teams for varying platforms – meaning they can focus on designing the application and port the end result to various support formats.
Forefront manufacturers shipping devices with native Adobe Air support include Acer, HTC, Motorola, RIM and Samsung. For consumers interested in existing devices the official Adobe site provides a listing of Abobe Air compatible mobile devices which meet the initial requirements.
Samsung will be the pioneer company to use Adobe Air in their upcoming SmartTV series. The SmartTV's are set to run social network and "web connected" applications through a simple and intuitive user interface. Samsung aims to allow users to browse online applications such as Facebook, email and web TV platforms like Hulu all via their living room couch. Surely this is Samsung's answer to Sony's GoogleTV.
As mentioned above Adobe also threw in additional desktop support for Adobe Air 2.5 which included CSS font face support, CSS shadow support, H.264 video hardware decoding and a new "StageWebView" feature. StageWebView more specifically allows developers to integrated full HTML content rendering within AIR applications.
For more specific information on what is included in the release and what benefits now exist visit the official Adobe Air website.
The official Adobe Air download link is also available on the official site. Keep an eye out here for further information on the release.
Adobe Air 2.5 SDK
Adobe Applications
Samsung SmartTV
Turbo charge your website using Google's mod_pagespeed
Facebook Presence - Beast, Myth or Legend


text:
DELIMITER //
DROP PROCEDURE IF EXISTS P_startCalculate ;
CREATE PROCEDURE P_startCalculate(IN whichMonth DATETIME,IN isAutoBill INT)
BEGIN
		DECLARE num int DEFAULT 0;
		#电话卡相关信息
		DECLARE cur_uuid VARCHAR(32);
		DECLARE cur_number VARCHAR(20);
		DECLARE cur_neoBussSatus INT(1);
		DECLARE contract_list VARCHAR(64) DEFAULT '';
		DECLARE plan_list VARCHAR(64) DEFAULT '';
		#账户的信息
		DECLARE cur_userName VARCHAR(32);
		DECLARE cur_userUuid VARCHAR(32);

		#循环控制变量
		DECLARE tmp_account_max INT DEFAULT 0;
		DECLARE tmp_account_min INT DEFAULT 0;
		DECLARE tmp_sim_max INT DEFAULT 0;
		DECLARE tmp_sim_min INT DEFAULT 0;
		DECLARE tmp_sim_count INT DEFAULT 0;

		#划价和结算的截止时间
		#Declare whichMonth DATETIME;

		#指示当neo_sim_card_settlement_statment表中已经有某卡的上月账单数据,则不再重复统计
		DECLARE flag_dataExist INT DEFAULT 0;

		#SET whichMonth = FROM_UNIXTIME(time_long);
		#用于指示当前的自动划价和自动计费任务是否正在执行
		IF(isAutoBill = 0) THEN
				UPDATE task_indicator SET task_status = 2 WHERE task_name = 'db_automprice';
				#自动划价时,设置划价的时间区间为当月1日-NOW()
				SET whichMonth = NOW();
		ELSE
				#自动计费时,首先判断当月数据是否已经生成,如果是的话,首先将已经成功扣费的用户的余额还原,再重新统计
				#避免自动计费重复运行导致的用户余额重复划扣
				UPDATE task_indicator SET task_status = 2 WHERE task_name = 'db_automcharge';
		END IF;

		#创建临时表,存储当前用户的所有SIM卡信息
		#tmp_flag指示当前卡的转态,0:划价失败 1:划价正常 6:达到封顶 8:短信或者流量超过套餐值
		DROP TABLE IF EXISTS tmp_sim;
		CREATE TEMPORARY TABLE IF NOT EXISTS tmp_sim(tmp_ts_id INT PRIMARY KEY auto_increment,tmp_sim_id VARCHAR(32),tmp_sim_num VARCHAR(11),tmp_neo_status INT,tmp_online_status INT,tmp_contract_list VARCHAR(64),tmp_plan_list VARCHAR(64),tmp_flag INT DEFAULT 1);

		#创建临时表,存储用户的当前信息
		DROP TABLE IF EXISTS tmp_account_balance;
		CREATE TEMPORARY TABLE IF NOT EXISTS tmp_account_balance(tmp_tab_id INT PRIMARY KEY auto_increment,tmp_user_id VARCHAR(32),tmp_user_name VARCHAR(18),tmp_user_email VARCHAR(32),tmp_balance DOUBLE(8,2) DEFAULT 0,tmp_base_invoice DOUBLE(8,2) DEFAULT 0,tmp_actual_invoice DOUBLE(8,2) DEFAULT 0);
		#用于判断当月是否已经结算过,如果结算过,则只统计结算失败的用户
		SELECT COUNT(*) INTO flag_dataExist FROM account_monthly_bill WHERE EXTRACT(YEAR_MONTH from STR_TO_DATE(statistic_month, '%Y%m')) = EXTRACT(YEAR_MONTH from whichMonth);
		IF(flag_dataExist = 0) THEN
				INSERT INTO tmp_account_balance(tmp_user_id,tmp_user_name,tmp_user_email,tmp_balance) SELECT account_balance.user_id,user_name,email,balance FROM account_balance,x_user WHERE account_balance.user_id = x_user.user_id AND x_user.is_active = 1 AND x_user.`status`= 5;
		ELSE
				INSERT INTO tmp_account_balance(tmp_user_id,tmp_user_name,tmp_user_email,tmp_balance) SELECT account_balance.user_id,user_name,email,balance FROM account_balance,x_user,account_monthly_bill WHERE account_monthly_bill.user_id=account_balance.user_id AND account_balance.user_id = x_user.user_id AND isfail=2 AND EXTRACT(YEAR_MONTH from STR_TO_DATE(statistic_month, '%Y%m')) = EXTRACT(YEAR_MONTH from whichMonth);
		END IF;
		SELECT * from tmp_account_balance;

		SELECT MAX(tmp_tab_id) INTO tmp_account_max FROM tmp_account_balance;
		SELECT MIN(tmp_tab_id) INTO tmp_account_min FROM tmp_account_balance;
		WHILE(tmp_account_min <= tmp_account_max) DO
				SELECT tmp_user_id,tmp_user_name INTO cur_userUuid,cur_userName FROM tmp_account_balance WHERE tmp_tab_id = tmp_account_min;
				SELECT COUNT(*) INTO tmp_sim_count FROM sim_card_info WHERE sim_card_info.user_name = cur_userName AND neo_business_status = 1;
				IF (tmp_sim_count >0) THEN
						#清空SIM卡临时表,重新插入下一个用户的数据
						TRUNCATE TABLE tmp_sim;
						INSERT INTO tmp_sim(tmp_sim_id,tmp_sim_num,tmp_neo_status,tmp_online_status,tmp_contract_list,tmp_plan_list)
						SELECT sim_card_info.id,phone_num,neo_business_status,online_status,GROUP_CONCAT(neo_contract.id),GROUP_CONCAT(neo_contract.plan_id)
						FROM sim_card_info,sim_card_status,neo_contract
						WHERE sim_card_info.id = sim_card_status.id AND sim_card_status.id = neo_contract.sim_id AND sim_card_info.user_name = cur_userName AND sim_card_info.neo_business_status = 1 AND F_statisticsOrNot(sim_card_info.id,whichMonth) = 1 AND (neo_contract.expiration_time > whichMonth OR '0000-00-00 00:00:00'= neo_contract.expiration_time)
						GROUP BY sim_card_info.id;
						#SELECT cur_userName,tmp_ts_id,tmp_sim_id,tmp_sim_num,tmp_neo_status,tmp_contract_list,tmp_plan_list,tmp_flag FROM tmp_sim;
						SELECT MAX(tmp_ts_id) INTO tmp_sim_max FROM tmp_sim;
						SELECT MIN(tmp_ts_id) INTO tmp_sim_min FROM tmp_sim;
						WHILE(tmp_sim_min <= tmp_sim_max) DO
								SELECT tmp_sim_num,tmp_neo_status,tmp_plan_list,tmp_contract_list INTO cur_number,cur_neoBussSatus,plan_list,contract_list FROM tmp_sim WHERE tmp_ts_id = tmp_sim_min;
								#用于判断当前卡是否已经成功统计
								SELECT COUNT(*) INTO flag_dataExist FROM sim_card_monthly_bill WHERE phone_num = cur_number AND EXTRACT(YEAR_MONTH from STR_TO_DATE(statistic_month, '%Y%m')) = EXTRACT(YEAR_MONTH from whichMonth) AND isfail = 1 LIMIT 1;
								IF(cur_neoBussSatus = 1 AND flag_dataExist = 0) THEN
										#SELECT plan_list,contract_list,cur_number,cur_userUuid,whichMonth,isAutoBill,@actualTotalInvoice;
										CALL P_calculateOneCardBill(plan_list,contract_list,cur_number,cur_userUuid,whichMonth,isAutoBill,@actualTotalInvoice);
								END IF;
								SET num = num +1;
								SET tmp_sim_min = tmp_sim_min + 1;
								#SELECT * FROM tmp_sim;
						END WHILE;
						IF(isAutoBill = 0) THEN
								CALL P_sendEmailOrNot(cur_userName,whichMonth);
						ELSE
								CALL P_calculateAllAccountBills(cur_userName,cur_userUuid,whichMonth);
						END IF;
				END IF;
				#SELECT * from tmp_account_balance;
				SET tmp_account_min = tmp_account_min+1;
		END WHILE;
		IF(isAutoBill = 0) THEN
				UPDATE task_indicator SET task_status = 1 WHERE task_name = 'db_automprice';
		ELSE
				UPDATE task_indicator SET task_status = 1 WHERE task_name = 'db_automcharge';
		END IF;
		SELECT num '统计的SIM卡数量';
END;//
DELIMITER ;

#CALL P_startCalculate('2016-11-30 14:05:35',0);

redpajama_set_name: RedPajamaGithub


text:
These Portable Air Conditioners Will Keep You Cool All Summer Long
The best way to keep your home chilled without the fuss of a window-mounted unit.
By Brandon Carte
If you don't have central air conditioning or your setup just won't work with a window AC unit, don't lose hope and succumb to the sweltering heat just yet! A portable air conditioner can be your saving grace this summer. Compared to their window-mounted counterparts, portable air conditioners can be placed virtually anywhere in your home. They offer a much easier installation and are much more capable at cooling a room than a fan can.
The name "portable air conditioner" is a bit of a misnomer, and they're not as portable as one would think. Although they are on wheels, portable AC units still take up a significant amount of floor space and need to be placed away from the walls, so airflow isn't restricted. Another drawback is that they require a venting hose to extract your room's warm air. The hoses are thick, like a dryer-vent duct, and unfortunately need to be fed through a nearby window.
Portable air conditioners are a great option for renters who aren't allowed to install window units. They're also a smart choice for folks who want to move their AC unit from room to room or store it in the off-season. We've researched and evaluated more than a dozen different models. We compared their portability and setup, BTU capacity, energy efficiency, noise, and performance, to find the best ones worth shopping for.
We also scoured the internet reading reviews from authoritative publications, including our sister sites Good Housekeeping and Popular Mechanics — who tested the appliances in-house — and also read several customer reviews on sites like Amazon, Home Depot, and Best Buy. Here are our favorite picks to keep you cool and comfortable in your home.
Best Portable Pick
Whynter Elite Portable Air Conditioner
The Whynter Elite is the best portable air conditioner money can buy. It offers excellent cooling capabilities, a compact footprint, and a quiet output of just 50 dBA. The Elite ARC-122DS is recommended by Good Housekeeping as well as Your Best Digs for its 24-hour programmable timer, included remote, and versatility.
The Elite ARC-122DS can be used as an air conditioner, a fan, or an air dehumidifier. Other highlights include a self-evaporative system for getting rid of condensed water, intuitive controls with a built-in digital display, and a dual-hose design which means it cools more efficiently.
The air conditioner has a maximum cooling capacity of 12,000 BTU. According to the manufacturer, it's suitable for up to 400 square feet of living space. We appreciate its easy installation and rolling caster wheels, so you can quickly move it room to room when necessary.
More: Smart Air Conditioners That Connect to Wi-Fi
Best Budget
BLACK + DECKER Portable Air Conditioner
Although you can find portable air conditioners for prices as low as $200, unfortunately they just don't deliver the cooling performance you'll need. Those models are only capable of cooling small spaces up to around 100 square feet since they have capacities of just 800 BTUs (British thermal units). Most buyers will need at least 12,000 BTUs to cool up to 500 square feet.
This Black + Decker AC unit offers a 14,000 BTU capacity, making it a good pick for an office or bedroom. At around 70 dB, it is louder than our top pick — however, we do appreciate its inclusion of a "Sleep Mode," which dims its LED lights, lessens its fan speed, and automatically shuts itself off after 8 hours. It includes a remote control and has a digital display for quickly adjusting settings. The unit rolls easily on casters and is even equipped with handles for transport.
Frigidaire Cool Connect Smart Portable Air Conditioner
This offering from Frigidaire sports a modern, streamlined cylindrical design that's unlike anything else on the market. The smart appliance blends seamlessly into any room and will complement your home décor better than any other AC unit. It's taller and more slender than the competition, so it takes up less space.
You can remotely turn the unit on or off, change temperature, and control mode and fan speeds using your smartphone. It'll even remind you when its filter needs replacing!
Like our "Best Splurge" pick, this one also links to your smart speaker for changing the temperature and turning it on using your voice. It can be controlled manually with the included remote, too. Most importantly, its distribution of cold air evenly reaches every corner of your room. This pick has enough power to cool rooms up to 550 square feet. It's a favorite of Business Insider for its built-in air purifier, stylish design, adjustable settings, and, of course, its useful smart features.
Best Splurge
LG Smart Wi-Fi Portable Air Conditioner
This portable air conditioner by LG impressed us with its sleek looks and smart functionality. Thanks to its Wi-Fi connectivity, you can easily schedule operating times, or even turn it on when you're not at home. It also pairs with your Amazon Alexa or Google Assistant-powered smart speaker, so you can adjust settings or power it off and on.
The unit covers areas up to 500 square feet and offers an extremely quiet operation — just 44 decibels to be exact. For context, a whisper measures in at 15 decibels, a window AC is typically around 60 decibels, and a lawn mower is roughly 90 decibels.
According to Wirecutter, the unit offers a good blend of cooling performance and efficiency. That's all thanks to its unique, variable-speed dual-rotor compressor. While other AC units have a single rotor that runs at just two speeds, LG's inverter compressor constantly adjusts its speed to maintain desired temperature levels, resulting in less fluctuation and better energy efficiency.
We think given its reliability, quiet operation, and useful smart features, the LG is definitely worth splurging for. That is, if you have the budget for it.
Best for a Quiet Operation
Honeywell Portable Air Conditioner
If you don't want to spend more than $600 for an air conditioner, but need one that won't disrupt your sleep schedule, we recommend this option from Honeywell. It's stylish, powerful, and rated at 49 decibels, making it quieter than most. It's about as loud as two people conversing in a room.
Our colleagues at Popular Mechanics tested this unit. They said that while it's not built for the biggest of rooms, it's worth a look for apartment dwellers who can't stand the steady whirr of your typical AC unit.
We appreciate its dual, washable filters that help improve air quality and eliminate dust and pet hair. This unit also comes with a remote control and features a "Sleep Mode" that increases the temperature at fixed intervals to cut down on energy costs, while still keeping you comfortable at night.
The Best Smoker Grills for Mouthwatering Meals
Brandon Carte Technology Editor Brandon Carte has been the technology editor at BestProducts.com since 2017, where he's been covering the latest gadgets and scouring the internet for the greatest deals; His tech reporting has been featured on TopTenReviews.com and USA Today.
More From Spring Into Summer Decor Inspiration
Eco-Friendly Items to Swap Out Single-Use Plastic
15 Doormats That Clean Up Your Entryway's Act
The Best Scented Candles for Every Possible Mood
10 Outdoor Fire Pits for Glowing Get-Togethers
20 Super-Fun Lawn Games to Break Out This Summer
This Giant Pool Float Is a Summer Must-Have
The Ultimate Outdoor Summer Party Essentials Guide
Linen Sheets Are the Epitome of Casual Coziness
Summer Pool Parties Just Got a Serious Upgrade
Find Us Under These Beach Umbrellas This Summer
Spring Into Summer Decor Inspiration
We Researched Top Air Conditioners to Find the Best
Window Fans That Boost Air Circulation
Electric Fans for Every Room in Your Home
7 Air Conditioners That'll Help You Keep Your Cool
A Portable Power Supply Can Up Your Glamping Game


text:
Home > Shows > Future Science
Date Thursday - March 17, 2011
Guests Michio Kaku, Dr. John Apsley
Natural Radiation Protection
The Next Wave of Science
Programmable Matter & Future Medicine
Theoretical physicist Dr. Michio Kaku discussed where science is taking us over the next century, and presented revolutionary developments in medicine, computers, quantum physics, and space travel. He pointed to four areas which will propel the evolution of science over the next 100 years: biotechnology, artificial intelligence, nanotechnology, and telecommunications. To that end, he surmised that someone from the year 2100 will be able to move things with their mind, possess "near perfect," ageless bodies, travel via flying vehicles propelled by super magnets, and have the ability to create a variety of unique creatures using genetics. "We're going to become the Gods that we once feared and worshipped," Kaku said.
One advancement which he foresees arriving in the "near future" is a form of contact lens which will be connected to the Internet. This "augmented reality," Kaku said, would allow for scenarios like being able to know all about a person as soon as you meet them and having subtitles printed beneath their face if they are speaking in a foreign language. He noted that such a device would be particularly popular for artists, since they could "conjure up new worlds, because it is in your contact lens." Additionally, it would also provide a boon for industries like architecture and tourism as well as the military, who are well on their way to designing an eye piece with these specifications. "Virtual reality is for children," he quipped, "but augmented reality is for adults, because it will help us work, play, and meet people."
Kaku also detailed how "programmable matter" is leading towards a world where shape shifting could become a reality. He explained that, by creating a charged chip that is the size of a grain of sand, scientists could then program the tiny particles to stick to each other in a myriad of ways. Presently, the chips are being used to create simple shapes, but, in time, they could be used to construct more complex structures. "In the future," he envisioned, "we could create an entire city with the push of a button." While such advancements may sound farfetched, Kaku stressed that these forecasts come from his conversations with cutting edge researchers. "I'm not a science fiction writer, I'm a scientist," he said, "and I've interviewed my colleagues and they tell me stories you wouldn't believe about what's possible in the future."
Radiation Protection:
In the first hour, cancer researcher Dr. John Apsley talked about natural methods for radiation protection. He warned that "there is really no safe level of radiation" and lamented that, since it has a half-life of 25,000 years, it is "constantly emitting destructive effects upon our cells" once inside the body. Apsley praised the benefits of kelp as a means of warding off the damage of radiation and shared the tale of two different Japanese hospitals which were about one mile away from the atomic blasts of World War II. One hospital used all natural seaweed and vegetables and the other used commercial foods. In the former institution, "virtually 100 percent" of the people lived, while, in the latter hospital, all of the people died.
News segment guests Catherine Austin Fitts talked about how the disaster in Japan affects the US economy and Dr. Bob Curran talked about St. Patrick's Day.
mkaku.org
doctorapsley.com
Physics of the Future
The Regeneration Effect
St. Patrick's Day Tribute Video
In honor of St. Patrick's Day, frequent C2C guest and accomplished singer, Christian Wilde, created a video featuring his rendition of "Danny Boy" and paying tribute to Irish-American movies and actors from the Golden Age of film. You can check out the video on YouTube and hear more of Wilde's music at his website.
Bumper music from Thursday March 17, 2011
Christian Wilde
Too-Ra-Loo-Ra-Loo-Ral (That's an Irish Lullaby)
I'm Looking Over A Four Leaf Clover
Art Mooney
John Gary
Remote Viewing Warnings
San Pedro Haunting Case


text:
{-# LANGUAGE CPP #-}
module Main
       ( main -- :: IO ()
       ) where

import Criterion.Main
import Crypto.Sign.Ed25519

import Data.Maybe (fromJust)
import Control.DeepSeq
import qualified Data.ByteString as B

--------------------------------------------------------------------------------

#if !MIN_VERSION_bytestring(0,10,0)
instance NFData B.ByteString
#endif

instance NFData SecretKey
instance NFData PublicKey

--------------------------------------------------------------------------------

main :: IO ()
main = do
  -- Don't use `createKeypair`, since that will incur a ton of calls
  -- to the OS to generate randomness. Simply generate a bogus Ed25519
  -- seed instead.
  let seed         = B.pack [0..31]
      keys@(pk,sk) = fromJust (createKeypairFromSeed_ seed)

      -- Generate a dummy message to sign, and a signature to verify
      -- against.
      dummy = B.pack [0..255]
      msg = sign sk dummy
  defaultMain
    [ bench "deterministic key generation"   $ nf createKeypairFromSeed_ seed
    , bench "signing a 256 byte message"     $ nf (sign sk)              dummy
    , bench "verifying a signature"          $ nf (verify pk)            msg
    , bench "roundtrip 256-byte sign/verify" $ nf (signBench keys)       dummy
    ]

signBench :: (PublicKey, SecretKey) -> B.ByteString -> Bool
signBench (pk, sk) xs = verify pk (sign sk xs)


text:
Orthomolecular Medicine News Service, July 19, 2021
Coming Straight Out of Perdition
Viral news from the nether regions
Satire by Andrew W. Saul, Editor
(OMNS July 19, 2021) What follows is an editorial that is purported to have been recently published in the Daily Hellion newspaper:
Lincoln was right when he said, "You can't fool all of the people all of the time." And there is no need to. We just have to fool most of the people most of the time. We have long worked to put the "demon" into democracy. COVID has done it splendidly. Even Hades' own think tanks (and we have tanks full of thinkers in Hell) did not seriously expect the vast majority of the world's entire population to placidly wear face masks for months on end. Even more delightful was the discovery that the majority so willingly fell into line the moment politicians and unelected "health" authorities invoked "emergency powers." Such cooperation was promptly rewarded by locking citizens down from their lives, their liberty, and their pursuit of happiness.
Our crowning achievement was to monetize mass medical misery. Our partners in the pharmaceutical industry really rose to the occasion, as their record of previous convictions predicted they would. Big pharma has never been known to turn down dump trucks full of cash. Neither they, nor the governments that pushed their products for them, can be held legally liable. The hastily "tested" experimental shots have killed thousands and injured hundreds of thousands. And it was all paid for by the victims' own tax money. Dillinger and Capone never had such a racket as this.
It was television that sealed the deal. Non-stop bludgeoning with "Stay home; stay safe" resulted in "Be depressed; eat more." An already overweight population was kept even more sedentary, put on the dole, and scared six ways from Tuesday. For months and months and months. But the stroke of genius was to give the public the illusion of being informed and cared for while completely misdirecting them. The ubiquitous TV message was, "COVID will kill you and there is no preventive and no effective treatment. So stay put until we get you your life-saving vaccine."
Admittedly, we almost fumbled the ball when word slipped out that a number of existing therapies, including vitamins C and D, were being used to treat COVID with excellent success. But we totally flushed that message beneath a whirlpool of never-ending fear mongering. It was easy. The mass media well know and dutifully practice the old adage: "If it bleeds, it leads." Plus, media get their income from pharmaceutical advertising and depend on government for their broadcast licenses and access to press conferences. So we knew we had the media from the start. Objective, balanced reporting was not even possible, let alone likely.
But we really nailed it down when we took over the social media so fast it would make Joseph Goebbels blush. Any serious discussion of fighting COVID by strengthening your immune system was promptly trashed by mercenary "fact checkers." Building the body's resistance through exercise and dietary supplementation became taboo. Entire Facebook pages with hundreds of thousands of followers vanished. Wikipedia pages were scrubbed and YouTube videos censored.
We will continue to press our hell-bent narrative: the virus is the only enemy; the human body is only a sitting duck; only the government has the answers; only the pharmaceutical cartel has the vaccine.
If only the populace knew the truth. If people start looking into nutritional prevention and treatment, they will no longer shut up, smile, and just get their shot.
We can't have that, now, can we?
(This editorial commentary by Andrew W. Saul does not necessarily represent the views of all members of the Orthomolecular Medicine News Service Editorial Board.)
Nutritional prevention and treatment of COVID has been the subject of several dozen Orthomolecular Medicine News Service releases. The articles are fully referenced, peer-reviewed, and free-access at http://www.orthomolecular.org/resources/omns/index.shtml , in English, Spanish, and many other languages.
And, should you be in the mood for them, there are additional satirical commentaries:
Marginalizing Megadosing Mammals: A Special Report Leaked from the World Headquarters Of Pharmaceutical Politicians, Educators, and Reporters. http://orthomolecular.org/resources/omns/v10n19.shtml
Selective Evidence Based Medicine Takes a New Turn http://orthomolecular.org/resources/omns/v08n11.shtml
How to Fool All of the People All of the Time http://orthomolecular.org/resources/omns/v06n05.shtml
How to Destroy Confidence in Vitamins When You Do Not Have the Facts http://orthomolecular.org/resources/omns/v06n02.shtml
Multivitamins Dangerous? Latest News from the World Headquarters Of Pharmaceutical Politicians, Educators and Reporters http://orthomolecular.org/resources/omns/v06n15.shtml
Albert G. B. Amoa, MB.Ch.B, Ph.D. (Ghana)
Seth Ayettey, M.B., Ch.B., Ph.D. (Ghana)
Gilbert Henri Crussol, D.M.D. (Spain)
Ian Dettman, Ph.D. (Australia)
Damien Downing, M.B.B.S., M.R.S.B. (United Kingdom)
Susan R. Downs, M.D., M.P.H. (USA)
Ron Ehrlich, B.D.S. (Australia)
Hugo Galindo, M.D. (Colombia)
Claus Hancke, MD, FACAM (Denmark)
Felix I. D. Konotey-Ahulu, MD, FRCP, DTMH (Ghana)
Alan Lien, Ph.D. (Taiwan)
Zhiyong Peng, M.D. (China)
Isabella Akyinbah Quakyi, Ph.D. (Ghana)
Garry Vickar, M.D. (USA)
Associate Editor: Robert G. Smith, Ph.D. (USA)
Editor, French Edition: Vladimir Arianoff, M.D. (Belgium)
Editor, Norwegian Edition: Dag Viljen Poleszynski, Ph.D. (Norway)
Editor, Arabic Edition: Moustafa Kamel, R.Ph, P.G.C.M (Egypt)
Editor, Korean Edition: Hyoungjoo Shin, M.D. (South Korea)
Editor, Spanish Edition: Sonia Rita Rial, PhD (Argentina)
Assistant Editor: Helen Saul Case, M.S. (USA)
Technology Editor: Michael S. Stewart, B.Sc.C.S. (USA)
Legal Consultant: Jason M. Saul, JD (USA)
Click here to see a web copy of this news release: https://orthomolecular.acemlna.com/p_v.php?l=1&c=199&m=203&s=d7513899274779d492d4c6d9101c3a1e
This news release was sent to gsaville4@bigpond.com. If you no longer wish to receive news releases, please reply to this message with "Unsubscribe" in the subject line or simply click on the following link: unsubscribe . To update your profile settings click here .


Blowout Sale! Up to 59% off on Shedding Tools at Annie's Dog Spa. Top brands include Hertzko, EASTOP, Wirezoll, PETTOOL, Conair, Music City Pet Shoppe, Safari Pet Products, Cavalier Pets, SERAIN, DELE, BUYBAR, Ihoming, iPrimio, BOSHEL, WAHL, Furminator, KlipspringerTrek., Aaronco Pet Products, ShearsDirect, & Evolution. Hurry! Limited time offers. Offers valid only while supplies last.


text:
Texas Hunt Lodge will you put you on a Trophy Black Hawaiian Sheep you'll want to hang on your wall and enjoy for years to come. We have the very best selection of Trophy Black Hawaiian Sheep to be found anywhere in the world. There are no seasonal restrictions on hunting the Black Hawaiian Sheep in Texas, which makes it a suitable trophy year round.
We typically let our hunters choose the method of hunting Trophy Black Hawaiian Ram that they prefer. Hunters of Trophy Black Hawaiian Sheep can choose the Spot and Stalk method, Bow Hunting, Rifle Hunting, Black Powder, Safari Style Hunting, Handgun, as well as hunting from a Blind. We can accommodate hunters of any age and experience level, as well as hunters which have physical disabilities or may be confined to a wheelchair.
In addition to the Black Hawaiian Ram, we also have other sheep of the Corsican Sheep family including the Texas Dall Sheep and the Painted Desert Sheep.
Black Hawaiian Trophy Fees
Trophy Black Hawaiian Ram (Average 30"): $2,500
Record Black Hawaiian Ram (37-40"): $4,500
The Black Hawaiian Sheep is derived from Texas actually, not Hawaii. Breeders in Texas, decades ago, took Mouflon and crossed them with domestic sheep, and created the Corsican Rams, Texas Dall Rams, Black Hawaiian Rams and Painted Desert Rams. Unlike the Mouflon, the Black Hawaiian Ram's horns grow like a corkscrew and get much longer than Mouflon Rams.
The Black Hawaiian Sheep, a member of the Corsican Ram family, is one of the most hunted of all the exotics in the United States. The Corsican is a hybrid sheep that began its history in Texas on the Y.O. Ranch about 40 years ago. There are several color variations to choose from when hunting a Corsican Sheep, and with these color variations come different names
The Hawaiian Black Sheep is black from head to hoof, with a splash of white on the muzzle. The Black Hawaiian Sheep has horns, not antlers, which do not shed and continue to grow. Black Hawaiian Sheep weigh between 130 and 160 lbs. The males have horns that can weigh 30 pounds, which is more than all the bones in his body combined. Horn length is typically 14 inches and up, and can reach up to 35 inches. Female Black Hawaiian Sheep, called ewes, also have horns that are smaller. The meat is edible although it will have a gamey taste. There are several ways to marinate and prepare the meat to help reduce the gamey taste.
Included with the Black Hawaiian Hunt Package
Below are some of the trophies taken from our Black Hawaiian hunts over the years.


Mother of Pearl Sterling Silver Money Clip | Shane Co.
This masculine money clip is crafted from quality polished sterling silver. The mother of pearl plating adds a bold blues look with a hint of sophistication.


text:
Aldnoah Zero is an epic anime and i really can't stress that enough.
Anyways, after watching all of the episodes just now, i now have this very strong urge to share the episode 12's ending analysis of someone else. Why is it that its not my analysis of the show? Well, to put it bluntly, i'm too lazy at the moment so, i bring you youryandere's ENDING ANALYSIS!
SPOILER ALERT! READ AT YOUR OWN RISK!
"I wrote the following analysis of the ending of Aldnoah.Zero. As many of you can probably tell, I drew heavily from the posts of a number of users from reddit (as well as Wikipedia), and you've probably read a number of these ideas somewhere on reddit already. Also, this is meant to be entirely self-contained (hence the explanation of Piso's justice, rather than just a link).
Episode 12 of Aldnoah.Zero drew much criticism because it suggests, but does not totally confirm, the deaths of Inaho and Asseylum. The killing of these two main characters may seem abrupt at first glance, and leaves the watcher puzzled as to how the second season of Aldnoah.Zero would progress without these important characters. However, closer inspection of the underlying themes of Aldnoah.Zero reveals that these deaths are rather the results of masterful writing, and they are fully necessary in order for the anime to fully explore and flesh out its themes.
To begin take Inaho, the tactical genius who is arguably the greatest factor towards the survival of the Earthlings onboard the Deucalion. From the very first episode, Inaho is portrayed as a pragmatic figure, always taking calculated risks. Indeed, in each of his many confrontations with Martian Kataphracts Inaho decides on a plan that gives the best chances at success, recognizing that his and his comrades' individual survival is not guaranteed. For example, in episode 2, Inaho's friend Okisuke is disintegrated by an enemy Kataphract. Yet, Inaho proceeds with his plan, unfazed by the casualty. For the majority of the anime, it is utilitarianism of Inaho that grants him success and survival. Thus, Inaho's death in episode 12 is the ultimate fulfillment of this characterization; Inaho finally pays the price for these risks he has been taking. Though his plan does result in the overall success of the operation, it comes at the cost of his life.
On a deeper level, with the events of episode 12, Inaho's death is inevitable. As already discussed, Inaho had written off his emotions as they were unnecessary impediments to the success of his plans. Yet, while Inaho and Asseylum are still outside Saazbaum's landing castle, we see that Asseylum begins once again to doubt herself, putting herself as the blame for the hatred that exists between Martians and Earthlings. Inaho, listening to this, interjects, saying that that even without hatred wars would still be waged. Though he presents this under the guise of a logical fact, the watcher cannot help but wonder if the comfort Inaho offers to the princess foreshadows the strengthening of his emotions.
Sure enough, with the conclusion of the first season, Inaho finally makes an emotional decision. In his last moments before Slaine shoots him, Inaho does not act according to calculations. Rather than choosing the more rational decision of staying away from the princess after she is shot by Saazbaum, Inaho crawls even closer to Asseylum. When Slaine instructs Inaho to back off of the princess, Inaho makes the emotional, irrational decision to instead turn around with his own gun out, even though he is in no fighting condition. Inaho, acting for the first time upon his newfound emotions towards the princess, has violated his characterization. It is fitting, then, that this emotional decision leads to Inaho's undoing. Slaine, on the other hand, is the embodiment of emotions. His purpose revolves not around his own well-being but strictly that of the princess. His affection for Asseylum likely comes from the fact that she had saved his life in the past. Driven by this love, he performs several noble deeds for the princess including shooting one of Asseylum's assassins, approaching the emperor of Vers to save Asseylum, and enduring the torture of Count Cruhteo so that Asseylum might live. Though Slaine's characterization is markedly different from that of Inaho, he, like Inaho, is able to achieve his goals for most of the anime.
As the ending of Aldnoah.Zero draws near, Slaine's emotions which had served him well so far become his downfall. A number of events sway Slaine to view the Martian cause more favorably: Count Cruhteo briefly shows sincere repentance and kindness to Slaine after having tortured him, Count Saazbaum takes Slaine in and nurses him back to health, and a Martian soldier recognizes Slaine as an ally of equal status. These all influence Slaine's emotional mindset, which is ultimately manifested in his saving of Count Saazbaum. Soon after, Slaine is unable to fire the final shot into Count Saazbaum, further reflecting the fact that Slaine's emotions have betrayed his purpose. This paradoxical behavior of rescuing one who is hell-bent on assassinating the princess can only be justified by the effect of recent events on Slaine's emotions. As a result of Slaine's emotions, Count Saazbaum has the opportunity to shoot the princess, which he immediately takes. This, combined with seeing the princess' fondness for Inaho, puts Slain into a rampage, shooting both Count Saazbaum and then Inaho (an idea we will explore in what follows). As such, in the first season of Aldnoah.Zero, emotions result in Slaine's failure to protect the princess. It is not unreasonable to expect that the second season of Aldnoah.Zero will continue to detail the decay of him as a character. For example, should Asseylum have survived the shot, Slaine may resort to underhanded and unethical tactics in order to hide the truth of Inaho's death from her, bringing him deeper and deeper into moral wretchedness. Then the final scene of the opening song may foreshadow Asseylum's revenge on Slaine upon discovering the truth, in which case Slaine will have been completely undone by the one he had so desperately tried to save – all due to Slaine's tendency for emotion.
Furthermore, the ending to Aldnoah.Zero is more than just the completion of the characterizations of Inaho and Slaine. Its subtitle, "Let Justice Be Done Though the Heavens Fall", derives from the Latin legal phrase "Fiat justitia ruat caelum". In one of its classical forms, this phrase refers the story of Piso's justice. According to this tale, the Roman governor Piso, while he was angry, ordered the execution of a soldier who had returned without his comrade on the grounds that if he could not produce his companion, he had presumably killed him. As the soldier was about to be executed, however, the very comrade who had supposedly been murdered appeared. The executioner thus halted the execution and brought the condemned soldier back to Piso, expecting a reprieve. But Piso, in his rage, ordered for the three of them to be executed. The condemned man was to be executed as his sentence had already passed, the executioner because he failed to carry out his duty, and the man who appeared because he had been the cause of the death of two innocent men. Today Piso's justice is viewed as a justice carried out under the influence of emotion that may have been technically correct, but morally wrong.
Piso's justice is analogous to the three deaths that conclude the first season of Aldnoah.Zero. Here Asseylum is the condemned soldier whose sentence is long overdue. It is only after many attempts on her life and near death experiences that she is finally, but wrongfully, put to death. Count Saazbaum is the executioner who had failed to carry out his duty the first time. Lastly, Inaho is the third man. Inaho shows up at an opportune time, able to save the princess on multiple occasions. However, in the eyes of Slaine (who in this allusion is Piso), Inaho simply endangered the princess with his plots and defeated the count. From the watcher's perspective, indeed Slaine has carried out a justice driven by emotion that is morally wrong. Though Piso's justice ends here, Piso's story goes on. In an unrelated event, Piso is put on trial by the emperor of Rome. However, this trial never occurs as Piso died, with rumors claiming that Piso was poisoned by the emperor. This supports the previous prediction that Asseylum may have survived to eventually extact her revenge on Slaine in the second season.
Urobuchi Gen, the concept designer for Aldnoah.Zero, is well known for his anime that criticize utilitarian justice (for example, Psycho-Pass). With the both seasons of Aldnoah.Zero perhaps Urobuchi is trying to address the flaws within an emotion-based justice like the one Slaine carried out. Whether this is true or not, the first season of Aldnoah.Zero has already illustrated several important points about human emotion. First, that emotion is intrinsic in human existence; even the most stoic man cannot avoid it. Second, that emotion, especially in excess, creates paradoxical behavior which easily leads to ruin. Therefore, the ending of Aldnoah.Zero is neither abrupt nor existing purely to provide shock. Instead, it is the culmination of masterful writing and character development.
EDIT: changed "death of Slaine" to "death of Inaho" in the second paragraph
TL;DR: Inaho's death makes sense because of the kind of character he is. It is fitting that upon his emotions influencing his actions, he dies. Slaine on the other hand is very emotional. However, his strong emotions prove to be his downfall. The events leading up to the ending only confuse Slaine as to whether he should side with the Martians who are trying to kill the princess or the princess. This results in him saving Count Saazbaum, who in turn kills Asseylum, undoing Slaine. Also, the three deaths in the ending of Aldnoah.Zero allude to Piso's justice (discussed in greater detail in the third and second to last paragraphs)."
…And yeah, this is the link of the original post.
Anime, Rant, Video


text:
<?php
# Generated by the protocol buffer compiler.  DO NOT EDIT!
# source: google/cloud/dialogflow/v2/context.proto

namespace Google\Cloud\Dialogflow\V2;

use Google\Protobuf\Internal\GPBType;
use Google\Protobuf\Internal\RepeatedField;
use Google\Protobuf\Internal\GPBUtil;

/**
 * The request message for [Contexts.CreateContext][google.cloud.dialogflow.v2.Contexts.CreateContext].
 *
 * Generated from protobuf message google.cloud.dialogflow.v2.CreateContextRequest
 */
class CreateContextRequest extends \Google\Protobuf\Internal\Message
{
    /**
     * Required. The session to create a context for.
     * Format: `projects/<Project ID>/agent/sessions/<Session ID>` or
     * `projects/<Project ID>/agent/environments/<Environment ID>/users/<User
     * ID>/sessions/<Session ID>`.
     * If `Environment ID` is not specified, we assume default 'draft'
     * environment. If `User ID` is not specified, we assume default '-' user.
     *
     * Generated from protobuf field string parent = 1 [(.google.api.field_behavior) = REQUIRED, (.google.api.resource_reference) = {
     */
    private $parent = '';
    /**
     * Required. The context to create.
     *
     * Generated from protobuf field .google.cloud.dialogflow.v2.Context context = 2 [(.google.api.field_behavior) = REQUIRED];
     */
    private $context = null;

    /**
     * Constructor.
     *
     * @param array $data {
     *     Optional. Data for populating the Message object.
     *
     *     @type string $parent
     *           Required. The session to create a context for.
     *           Format: `projects/<Project ID>/agent/sessions/<Session ID>` or
     *           `projects/<Project ID>/agent/environments/<Environment ID>/users/<User
     *           ID>/sessions/<Session ID>`.
     *           If `Environment ID` is not specified, we assume default 'draft'
     *           environment. If `User ID` is not specified, we assume default '-' user.
     *     @type \Google\Cloud\Dialogflow\V2\Context $context
     *           Required. The context to create.
     * }
     */
    public function __construct($data = NULL) {
        \GPBMetadata\Google\Cloud\Dialogflow\V2\Context::initOnce();
        parent::__construct($data);
    }

    /**
     * Required. The session to create a context for.
     * Format: `projects/<Project ID>/agent/sessions/<Session ID>` or
     * `projects/<Project ID>/agent/environments/<Environment ID>/users/<User
     * ID>/sessions/<Session ID>`.
     * If `Environment ID` is not specified, we assume default 'draft'
     * environment. If `User ID` is not specified, we assume default '-' user.
     *
     * Generated from protobuf field string parent = 1 [(.google.api.field_behavior) = REQUIRED, (.google.api.resource_reference) = {
     * @return string
     */
    public function getParent()
    {
        return $this->parent;
    }

    /**
     * Required. The session to create a context for.
     * Format: `projects/<Project ID>/agent/sessions/<Session ID>` or
     * `projects/<Project ID>/agent/environments/<Environment ID>/users/<User
     * ID>/sessions/<Session ID>`.
     * If `Environment ID` is not specified, we assume default 'draft'
     * environment. If `User ID` is not specified, we assume default '-' user.
     *
     * Generated from protobuf field string parent = 1 [(.google.api.field_behavior) = REQUIRED, (.google.api.resource_reference) = {
     * @param string $var
     * @return $this
     */
    public function setParent($var)
    {
        GPBUtil::checkString($var, True);
        $this->parent = $var;

        return $this;
    }

    /**
     * Required. The context to create.
     *
     * Generated from protobuf field .google.cloud.dialogflow.v2.Context context = 2 [(.google.api.field_behavior) = REQUIRED];
     * @return \Google\Cloud\Dialogflow\V2\Context|null
     */
    public function getContext()
    {
        return $this->context;
    }

    public function hasContext()
    {
        return isset($this->context);
    }

    public function clearContext()
    {
        unset($this->context);
    }

    /**
     * Required. The context to create.
     *
     * Generated from protobuf field .google.cloud.dialogflow.v2.Context context = 2 [(.google.api.field_behavior) = REQUIRED];
     * @param \Google\Cloud\Dialogflow\V2\Context $var
     * @return $this
     */
    public function setContext($var)
    {
        GPBUtil::checkMessage($var, \Google\Cloud\Dialogflow\V2\Context::class);
        $this->context = $var;

        return $this;
    }

}